- Previous Close
8.00 - Open
8.03 - Bid --
- Ask 7.53 x 100
- Day's Range
7.41 - 8.08 - 52 Week Range
6.76 - 13.50 - Volume
81,871 - Avg. Volume
55,867 - Market Cap (intraday)
299.898M - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
-- - EPS (TTM)
-1.94 - Earnings Date May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.04
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
www.nyxoah.comRecent News: NYXH
View MorePerformance Overview: NYXH
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is BEL 20 (^BFX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NYXH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NYXH
View MoreValuation Measures
Market Cap
286.19M
Enterprise Value
218.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
51.58
Price/Book (mrq)
2.35
Enterprise Value/Revenue
44.70
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.02%
Return on Equity (ttm)
-56.08%
Revenue (ttm)
4.52M
Net Income Avi to Common (ttm)
-59.24M
Diluted EPS (ttm)
-1.94
Balance Sheet and Cash Flow
Total Cash (mrq)
85.56M
Total Debt/Equity (mrq)
20.00%
Levered Free Cash Flow (ttm)
-31.69M